Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flot2-silenced Pmel-1 CD8+ T cells
- Development stage
- Preclinical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Flot2-silenced Pmel-1 CD8+ T cells** are a genetically engineered cell therapy derived from Pmel-1 TCR-transgenic CD8+ T cells, in which the **Flotillin-2 (Flot2)** gene has been silenced, likely via RNA interference, to enhance anti-tumor efficacy. Pmel-1 CD8+ T cells are specific for the melanoma antigen **gp100 (pmel17)** and serve as a standard model for adoptive T cell therapy against **B16 melanoma**. Flot2 silencing disrupts lipid raft formation, reducing inhibitory signaling and improving T cell persistence and cytotoxicity. No developer or clinical trial data is available; this appears to be an experimental modification in preclinical research.
- Other names
- Flotillin-2 silenced Pmel-1 CD8+ T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Flot2-silenced Pmel-1 CD8+ T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flot2-silenced Pmel-1 CD8+ T cells.